Skip to main content
SpringerLink
Log in

Was muss ich praktisch bei der Umsetzung einer Chemotherapie beachten?

What is practically important when carrying out a chemotherapy?

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Im Mittelpunkt der Durchführung einer Chemotherapie steht der Patient. Ziel der kurativen oder palliativen Behandlung ist nicht nur die Apoptose der Tumorzellen, sondern auch der Erhalt oder die Verbesserung der Befindlichkeit, insbesondere die Lebensqualitätssteigerung des Tumorkranken. Vor Beginn der Therapie sind allgemeine Voraussetzungen (z. B. Allgemeinzustand, Motivation, Aufklärung) und spezielle Untersuchungen (z. B. Blutuntersuchungen, Audiogramm, Nierenfunktion, Lungenfunktion) zu berücksichtigen. So kann im Vorfeld die Verträglichkeit der meistens belastenden Chemotherapie ermittelt und der Patient auf die Behandlung individuell vorbereitet werden.

Abstract

The patient stands at the center of a chemotherapy. The aim of the curative or palliative treatment is not only the death of the tumor cells, but also the maintenance or improvement of the patient’s physical condition, especially the improvement of quality of life. Before starting the therapy, it is necessary to determine, for example, the patient’s general condition and motivation, and to carry out a consultation. Examinations, for example, blood tests, audiograms, renal function and lung function should also be made. Thus, the patient’s tolerance for even the most onerous chemotherapy can be investigated and patients can be individually prepared for the treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Aapro M (2005) Optimising antiemetic therapy: what are the problems and how can they be overcome? Curr Med Res Opin 21(6): 885–897

    Article  PubMed  Google Scholar 

  2. Aaronson NK et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5): 365–376

    PubMed  Google Scholar 

  3. Bokemeyer C, Oechsle K, Hartmann JT et al. (2002) Treatment-induced anaemia and ist potential clinical impact in patients receiving sequential high dose chemotherapy for metastatic testicular cancer. Br J Cancer 87(10): 1066–1071

    Article  PubMed  Google Scholar 

  4. Cella DF et al. (1993) The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3): 570–579

    PubMed  Google Scholar 

  5. Chen CC et al. (2004) Utilization of comprehensive geriatric assessment in cancer patients. Crit Rev Oncol Hematol 49(1): 53–67

    PubMed  Google Scholar 

  6. DeVita VT, Hellman S, Rosenberg SA (2001) Cancer: principles and practice of oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia; Chapter 55, p 2869

  7. de Wit R et al. (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21(22): 4105–4111

    Article  PubMed  Google Scholar 

  8. Grahmann PR et al. (2005) [Respiratory failure and pulmonary fibrosis as a late side-effect after chemotherapy-induced by oxygen administration]. Pneumologie 59(11): 763–769

    Article  PubMed  Google Scholar 

  9. Hesketh PJ et al. (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8): 1074–1080

    Article  PubMed  Google Scholar 

  10. Horstman MG, Meadows GG, Yost GS (1987) Separate mechanisms for procarbazine spermatotoxicity and anticancer activity. Cancer Res 47(6): 1547–1550

    PubMed  Google Scholar 

  11. Hurria A et al. (2005) Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer. Drugs Aging 22(9): 785–791

    Article  PubMed  Google Scholar 

  12. MASCC – Consensus Conference Perugia (2004) – Multinational Association for Supportive Care in Cancer. Consensus Conference on Antiemetic Therapy, Perugia, March 29–31, 2004.http://www.mascc.org

  13. Mir O et al. (2005) Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 16(9): 1017–1021

    Article  PubMed  Google Scholar 

  14. Pizzo PA (1984) Granulocytopenia and cancer therapy. Past problems, current solutions, future challenges. Cancer 54(11 Suppl): 2649–2661

    PubMed  Google Scholar 

  15. Rademaker-Lakhai JM et al. (2006) Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24(6): 918–924

    Article  PubMed  Google Scholar 

  16. Roila F (2003) Multinational Association of Supportive Cancer Care (MASCC). Support Care Cancer 11(4): 260–261

    PubMed  Google Scholar 

  17. Sauer H (1998) [Systemic cytostatic chemotherapy]. Internist (Berl) 39(11): 1104–1114

  18. Weichert-Jacobson K (2000) Praxis der Chemotherapie. Urologe B 40: 275–281

    Article  Google Scholar 

Download references

Interessenkonflikt

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Urologische Universitätsklinik, Hufelandstraße 55, 45122, Essen

    M. Schenck & T. Jäger

Authors
  1. M. Schenck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Jäger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Schenck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schenck, M., Jäger, T. Was muss ich praktisch bei der Umsetzung einer Chemotherapie beachten?. Urologe 45, 572–579 (2006). https://doi.org/10.1007/s00120-006-1045-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-006-1045-3

Schlüsselwörter

Keywords

Search

Navigation